NAGE

Niagen Bioscience, Inc.

Nasdaq· Medicinal Chemicals & Botanical Products· Inc. DE· CIK 0001386570 Biotech & Drug Discovery

$2.44 +0.01 (+0.41%)

Oct 26 4:00 PM ET · prev $2.43

Market cap

$199.4M

Micro cap

Median target

$10.50

+330% · range $8.50–22.00

Next earnings

Nov 4

in 8 days · EPS est. −$0.03

1 year

−67.9%

from $7.60 · Oct 27

30 days

−18.1%

from $2.98

52-week range

$2.43–7.60

−68% from high · low Oct 23

Avg volume 20D

589.6K

Oct 2 spike 1.57M

Short interest

🔒 Subscribers only

Insider net

no open-market trades · 12 mo

New fund stakes

Q2 2026 13F · 0 exits

Filing reports

analyzed by SecBot

SecBot read BEARISH 2 reports · latest

Balance 2 bearish · 0 bullish oldest → newest, height = score

Avg score

·High conf. 1/2 ·Next Earnings date, Nov 4, 2026

Strongest BEARISH Niagen Bioscience filed a 424B5 prospectus supplement for an at-the-market offering of up to $50 million in…

All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

InsidersNO TRADES

No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.
InstitutionsMIXED

Q2 2026: 15 added (0 new), 20 trimmed or exited.
EstimatesFALLING

Current-quarter EPS estimate $0.030 → −$0.030 over 90 days. 0 up, 1 down in 30 days.
TrendDOWNTREND

16% below its 50-day average. New closing low $2.43 on Oct 23.

Who's buying

13F· Q2 2026

new positions

exits

Fund	Move	Shares	Value
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP	TRIM	1,171,215	$3.7M
RENAISSANCE TECHNOLOGIES LLC	TRIM	659,584	$2.1M
DIMENSIONAL FUND ADVISORS LP	TRIM	605,326	$1.9M
MORGAN STANLEY	ADD	504,772	$1.6M
SEI INVESTMENTS CO	TRIM	471,934	$1.5M
PANAGORA ASSET MANAGEMENT INC	ADD	347,207	$1.1M
MILLENNIUM MANAGEMENT LLC	TRIM	275,423	$878.6K
ROYAL BANK OF CANADA	ADD	247,063	$788.0K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action May 2026

12-month targets · 6 analysts

$2.44 $8.50 $10.50 $22.00

Price is below the lowest target. Median implies +330%.Targets as of Oct 27, 2026.

Recent actions

Date	Firm	Action	Rating
May 11, 2026	HC Wainwright & Co. MAINTAIN	MAINTAIN	Buy
May 5, 2026	Canaccord Genuity MAINTAIN	MAINTAIN	Buy

Insider ledger

Form 4

open-market buys or sells · 12 mo

Date	Insider	Type	Value
Jun 30, 2026	Fried Robert N Chief Executive Officer	AWARD	$3.0K
Jun 30, 2026	Pamir Ozan Chief Financial Officer	AWARD	$11.5K
Jun 30, 2026	Lopez Carlos Luis SVP, General Counsel	AWARD	$6.3K
Jun 24, 2026	Shahbazi Hamed Director	AWARD	31,746 sh
Jun 24, 2026	Patrick Kristin Director	AWARD	31,746 sh
Jun 24, 2026	Cohen Ann Director	AWARD	31,746 sh
Jun 24, 2026	Ng Wang Yu Gary Director	AWARD	31,746 sh
Jun 24, 2026	YU Wing Tak Wendy Director	AWARD	31,746 sh

Earnings setup

Estimates

Nov 4

reports in 8 days

−$0.03

EPS estimate, this quarter

−200%

estimate change, 90 days

0↑ 1↓

revisions, 30 days

Current-quarter EPS estimate

$0.030

90d

−$0.010

60d

−$0.010

30d

−$0.010

−$0.030

Now

Period	EPS est.	Range	30D rev.	Revenue
Current Q	-$0.03	-$0.03–-$0.03	-200.0%	$34.3M
Next Q	-$0.06	-$0.06–-$0.06	-700.0%	$37.7M
Current FY	$0.00	$0.00–$0.00	-100.0%	$133.2M
Next FY	-$0.06	-$0.06–-$0.06	-160.0%	$154.7M